XML 17 R5.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2023   112,639,146    
Beginning balance at Dec. 31, 2023 $ 482,597 $ 113 $ 1,267,469 $ (784,985)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net loss $ (26,067)     (26,067)
Exercise of stock options (in shares) 257,201 257,201    
Exercise of stock options $ 1,990 $ 0 1,990  
Issuance of common stock related to Spyce milestone achievement 2,132   2,132  
Issuance of common stock related to restricted shares (in shares)   208,042    
Issuance of common stock related to Spyce milestone achievement (in shares)   105,371    
Stock-based compensation expense 9,626   9,626  
Ending balance (in shares) at Mar. 31, 2024   113,209,760    
Ending balance at Mar. 31, 2024 470,278 $ 113 1,281,217 (811,052)
Beginning balance (in shares) at Dec. 29, 2024   117,116,311    
Beginning balance at Dec. 29, 2024 446,145 $ 117 1,321,386 (875,358)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net loss $ (25,039)     (25,039)
Exercise of stock options (in shares) 210,708 210,708    
Exercise of stock options $ 1,683 $ 1 1,682  
Issuance of common stock related to performance stock units (in shares)   0    
Issuance of common stock related to restricted shares (in shares)   341,116    
Shares repurchased for employee tax withholding (in shares)   (9,651)    
Shares repurchased for employee tax withholding (256)   (256)  
Stock-based compensation expense 10,221   10,221  
Ending balance (in shares) at Mar. 30, 2025   117,658,484    
Ending balance at Mar. 30, 2025 $ 432,754 $ 118 $ 1,333,033 $ (900,397)